FDA expands approval for Bayer's lung cancer therapy

The U.S. Food and Drug Administration announced an expansion of the approved use of Bayer's lung cancer drug.

The decision broadens the patient population eligible for the treatment, reflecting the regulator's ongoing efforts to keep pace with advances in oncology.

The move could influence Bayer's market positioning and is likely to be watched by investors focused on cancer drug pipelines.